Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Padmanabhan brings over two decades of extensive experience in FMCG sector
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Subscribe To Our Newsletter & Stay Updated